Pharmacology Services was the largest of Champions Oncology, Inc.’s 3 reported lines in fiscal 2026, at $57.13M — 96% of $59.43M.
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacology Services | $50.71M | $47.04M | $48.59M | $57.13M | |||||
| Other Tos Revenue | $3.05M | $3.10M | $3.68M | $1.53M | |||||
| Tos Data License Revenue | — | — | $4.68M | $764.00K | |||||
| Personalized Oncology Services | $116.00K | $18.00K | — | — | |||||
| Total | $53.87M | $50.16M | $56.94M | $59.43M |
In fiscal 2026, which ended April 30, 2026, the 3 revenue lines Champions Oncology, Inc. reported in this breakdown added up to $59.43M. That was up 4.4% from $56.94M in fiscal 2025. Pharmacology Services was the largest revenue line, at $57.13M or 96.1% of the total, followed by Other Tos Revenue ($1.53M, 2.6%) and Tos Data License Revenue ($764.00K, 1.3%). Together, the two largest revenue lines made up 98.7% of this total.
Compared with fiscal 2025, Pharmacology Services grew the fastest, rising 17.6% to $57.13M. Other Tos Revenue fell the most, down 58.5% to $1.53M.
Tos Data License Revenue was first reported as a separate revenue line in fiscal 2025. The table also keeps 1 revenue line that Champions Oncology, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2018 to 2026, as reported in Champions Oncology, Inc.'s annual filings.
Translational Oncology Solutions (Tos) was the largest of Champions Oncology, Inc.’s 2 reported lines in fiscal 2017, at $13.69M — 89% of $15.41M.
| Statement Business Segments | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|
| Translational Oncology Solutions (Tos) | — | — | $9.21M | $13.69M | ||
| Translational Oncology Solutions | $9.29M | $7.20M | — | — | ||
| Personalized Oncology Solutions (Pos) | — | — | $1.97M | $1.72M | ||
| Personalized Oncology Solutions | $2.26M | $1.66M | — | — | ||
| Total | $11.55M | $8.86M | $11.18M | $15.41M |
In fiscal 2017, which ended April 30, 2017, the 2 segments Champions Oncology, Inc. reported in this breakdown added up to $15.41M. That was up 37.8% from $11.18M in fiscal 2016. Translational Oncology Solutions (Tos) was the largest segment, at $13.69M or 88.8% of the total, followed by Personalized Oncology Solutions (Pos) ($1.72M, 11.2%).
Compared with fiscal 2016, Translational Oncology Solutions (Tos) grew the fastest, rising 48.7% to $13.69M. Personalized Oncology Solutions (Pos) fell the most, down 12.8% to $1.72M.
Translational Oncology Solutions (Tos) (fiscal 2016) and Personalized Oncology Solutions (Pos) (fiscal 2016) were first reported as separate segments during this period. The table also keeps 2 segments that Champions Oncology, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2012 to 2017, as reported in Champions Oncology, Inc.'s annual filings.
Champions Oncology, Inc. (CSBR) breaks its revenue down by revenue line and segment. In fiscal 2026, its largest revenue line was Pharmacology Services, with $57.13M or 96.1% of the total, followed by Other Tos Revenue at $1.53M (2.6%).
Pharmacology Services was Champions Oncology, Inc.'s largest revenue line in fiscal 2026, with $57.13M in revenue, 96.1% of the $59.43M reported across its 3 revenue lines.
Translational Oncology Solutions (Tos) was Champions Oncology, Inc.'s largest segment in fiscal 2017, with $13.69M in revenue, 88.8% of the $15.41M reported across its 2 segments.
Of the Champions Oncology, Inc. revenue lines reported in both fiscal 2025 and fiscal 2026, and making up at least 2% of the total, Pharmacology Services grew the fastest, rising 17.6% from $48.59M to $57.13M.
Every figure is taken from Champions Oncology, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2018 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.